| News

What we learned at this year’s DayOne Conference

19.10.2019

DayOne Conference 2019

Twenty-two panellists and speakers, among them 3 patients and digital health futurist Maneesh Juneja, 30 project champions and their mentors, 40 volunteers and 450 participants and Arcondis as conference Partner  — this was the DayOne Conference which took place on September 9 at the FHNW in Muttenz.

It is fair to say that the format, now in its fourth edition, has established itself, even though change in terms of location and order of events has been and will most probably continue to be constant, given the mission of DayOne to shape the future of health. What will remain are the basic ingredients – a growing community of healthcare innovators and their appetite to share their expertise and co-create with their peers.

Representing the vibrant healthcare ecosystem of the Basel region and beyond, the DayOne innovation community is attracting ever more entrepreneurs to attend the open innovation session at the conference; the session includes both applicants to the DayOne accelerator program and also ventures and projects for which feedback is sought. This big collaborative effort makes the DayOne Conference unique, even for entrepreneurs from abroad.

Also unique to the DayOne Conference is the openness to talk about neglected issues. One of these is – strangely enough for this industry – the need to include the patient’s view. In fact, the conference started and set the tone with a patients’ panel, followed by a session on future ethics in healthcare and a session on financing innovation – beyond venture capital.

The following are our personal takeaways from this year’s DayOne Conference:

1) Patient centricity is key: Even though starting with the patients seems the most obvious in healthcare innovation, there still seems to be considerable reluctance to accept this concept. The patient stories on stage clearly showed the necessity: As technology evolves, allowing new ways for patients to monitor and more efficiently (self)manage their health states, new applications will only succeed if they bring tangible value to end-users and improve their quality of life.

2) No trust, no business: Trust in technology is becoming a crucial factor for advancing innovation. Ethics therefore matter. Patients and individuals will only share their data for a good reason and if they get something out of it. In the long run, Health Data Ecosystems, the foundation of healthcare innovation, will not thrive in an environment of unilateral enforcement and exploitation.

3) De-risking investment through collaboration: Regarding the investments flowing into Digital Health, Europe seems to be losing out between the superpowers of the east (China) and west (USA). However, money cannot buy everything. What bright minds need most of all is innovation ecosystems where their ideas can be nourished and validated, providing access to healthcare providers and industry. Thus, building on a strong collaborative effort between stakeholders will stimulate entrepreneurial appetite and de-risk investments.

4) Entrepreneurs need diversity: Technology is there and ready to use. A key differentiator for digital health start-ups is the ability to make the best use of it. This requires a culture of integrating diverse capabilities, such as data sciences, medicine, research, patient/user experience and also commercialisation. In this respect, DayOne hubs with their community approach are becoming increasingly crucial for business creation.

(This report hast been co-authored by Manuel Kammermann, Arcondis)

A huge thank you for everyone who made this year’s DayOne Conference happen!

Canton of Basel-Stadt and BaselArea.swiss for facilitating. Our Conference Partner: Arcondis. 

The Patients: Cecile Tardy, Judith Safford, Peter Loewenberg

The Speakers and Panellist on Ethics: Nicholetta Iacobacci, Exponential Ethics; Evelyne Bischof, Shanghai Jiao Tong University School of Medicine; Bram Stieltjes, Universitätsspital Basel; Daniel R. Karlin, HealthMode; Athula Herath, Novartis; Erik Schkommodau, FHNW

The Speakers and on Financing: Andreas Igel, Arcondis; Julien de Salaberry, Galen Growth; Alex Buech, Medical Insights; Jan Vichr, Canopei; Sybille Fischer, Baloise; Gabor Szinnai, UKBB; Stephanie Bova, Takeda; Amine Korchi, Fusion; André Guedel, KPMG

Keynote: Maneesh Juneja, Digital Health Futurist, London

Moderation and Curation: Thomas Brenzikofer and Doug Häggström

Open Innovation Head Coaches: Aurelie Moser, Viktor Bullain, Egle B. Thomas

30 Projects Champions, their mentors and 40 Volunteers

And to our DayOne Conference supporting partners: MedInside, Swiss Healthcare Startups, CSEM, ETH Zürich- DBSSE, FHNW, Swiss Institute of Bioinformatics, Swiss TPH, UKBB, Universität Basel, Universitätsspital Basel, ELCA, SAS, Soladis Group

See the presentations

Check out the project’s work

Background read on the Future of Health 

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Basel Area Business & Innovation, Invest

Ricola earns the trust of Switzerland

Ricola has been voted the most trustworthy brand in Switzerland. The manufacturer of herbal candy, which is based in the Basel Area, previously won this award in 2017.

Read More
Basel Area Business & Innovation, Innovation

docdok.health involved in coronavirus research project

A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.

Read More
Basel Area Business & Innovation, Innovation

Celonic agrees cooperation to combat coronavirus

The Basel-based biopharmaceutical company Celonic Group has agreed a partnership with Airway Therapeutics from the USA. Together, the two companies are planning to develop a drug to treat coronavirus.

Read More
Basel Area Business & Innovation, Innovation, Invest

Idorsia receives payment of 45 million US dollars

The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..

Read More
Basel Area Business & Innovation, Innovation

Humard robot disinfects using UV light

Humard has developed a robot that can disinfect spaces using UV light. For this, the system manufacturer from the canton of Jura has adapted a mobile industrial robot that is otherwise used in warehouse logistics.

Read More
Basel Area Business & Innovation, Innovation, Invest

Roche authorized to distribute coronavirus antibody tests

Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.

Read More
Basel Area Business & Innovation, Invest

Basel is the most popular Swiss location for headquarters

Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.

Read More
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Healthtech sector growing rapidly in the Basel Area

The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.

Read More
Basel Area Business & Innovation, Innovation, Invest

Support program has roots in Basel

The online program Selfapy supports people suffering from mental health conditions during the coronavirus lockdown. BaselArea.swiss has provided startup help by way of its DayOne initiative.

Read More
Basel Area Business & Innovation, Innovation

University Hospital Basel treats coronavirus patients with plasma

The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.

Read More
1 2 3 18

Do you have a question? We'd like to hear from you.